Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 5, 2006

Power3 and University of Thessaly Partner on Parkinson's Disease

  • Power3 Medical Products will work with the University of Thessaly in Larissa, Greece, with a focus on the proteomic discovery of biomarkers for Parkinson's disease.

    The University of Thessaly will provide Power3 with clinically confirmed samples of neurodegenerative disease, including age- and gender-match controls. Power3 will analyze the samples for new protein biomarkers for the early detection of neurodegenerative diseases to add to its portfolio.

    The collaboration will also extend to cover other neurodegenerative diseases, including Alzheimer's disease and ALS.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »